GlassScriptPhysician profile
Noah M Solomon
NPI 1780674754
$2,982.79
in general payments reported to CMS, 2019-2025
26 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $308 · 2021: $431 · 2022: $679 · 2023: $678 · 2024: $353 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144 · Education: $90.82 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.45 |
| Education | $90.82 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $537.56 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $391.74 | 2019-2025 | Krystexxa |
| Horizon Therapeutics Plc | $243.83 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $228.94 | 2019-2024 | Lokelma, Farxiga |
| Alexion Pharmaceuticals, INC. | $176.87 | 2020-2025 | |
| Glaxosmithkline, LLC. | $165.27 | 2021-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $160.97 | 2019-2024 | Jynarque |
| Nxstage Medical, INC. | $144.90 | 2021-2023 | Nxstage System One |
| Travere Therapeutics, INC. | $122.74 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $105.03 | 2021-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $98.31 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $71.89 | 2024-2025 | |
| Veloxis Pharmaceuticals, INC. | $66.78 | 2023-2025 | Envarsus |
| Mallinckrodt Enterprises LLC | $66.26 | 2019 | |
| Aurinia Pharma U.S., INC. | $63.52 | 2021-2025 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $62.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.28 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $38.64 | 2022 | |
| Ani Pharmaceuticals, INC. | $36.43 | 2022 | |
| Baxter Healthcare | $28.46 | 2023 | Renal - Pd |
| Ardelyx, INC. | $25.98 | 2024 | Ibsrela |
| Amarin Pharma, INC. | $23.12 | 2021 | |
| Novo Nordisk INC | $20.02 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.83 | 2021 | |
| Abbvie INC. | $18.85 | 2022 | |
| Kyowa Kirin, INC. | $18.15 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.